Clinical Trial Update: BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update on blisibimod for IgA nephropathy, including at-home subcutaneous administration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• blisibimod (blisibimod)

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: IgA Nephropathy | Phase 2, Phase 3 | Status: COMPLETED